公开(公告)号：EP1519939B1

公开(公告)日：2009-12-09

申请号：EP03739358.4

申请日：2003-06-27

申请人： Targacept, Inc.

发明人： BHATTI, Balwinder, S. ,  MILLER, Craig, H. ,  SCHMITT, Jeffrey, D.

IPC分类号： C07D487/10 ,  C07D471/10 ,  A61K31/40 ,  A61K31/435

CPC分类号： C07D487/20 ,  C07D453/02 ,  C07D471/10 ,  C07D471/20 ,  C07D487/10

摘要： Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryldiazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic choligernic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: ( I ) alter the number of nicotinic cholinergic receptors of the brain of the patient, ( ii ) exhibit neuroprotective effects and ( iii ) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

公开(公告)号：EP1519939B9

公开(公告)日：2011-04-06

申请号：EP03739358.4

申请日：2003-06-27

申请人： Targacept, Inc.

发明人： BHATTI, Balwinder, S. ,  MILLER, Craig, H. ,  SCHMITT, Jeffrey, D.

IPC分类号： C07D487/10 ,  C07D471/10 ,  A61K31/40 ,  A61K31/435

CPC分类号： C07D487/20 ,  C07D453/02 ,  C07D471/10 ,  C07D471/20 ,  C07D487/10

公开(公告)号：EP1519939A2

公开(公告)日：2005-04-06

申请号：EP03739358.4

申请日：2003-06-27

申请人： Targacept, Inc.

发明人： BHATTI, Balwinder, S. ,  MILLER, Craig, H. ,  SCHMIDT, Jeffrey, D.

IPC分类号： C07D487/10 ,  C07D471/10 ,  A61K31/40 ,  A61K31/435

CPC分类号： C07D487/20 ,  C07D453/02 ,  C07D471/10 ,  C07D471/20 ,  C07D487/10

摘要： Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryldiazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic choligernic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: ( I ) alter the number of nicotinic cholinergic receptors of the brain of the patient, ( ii ) exhibit neuroprotective effects and ( iii ) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).